Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Treatment Strategies for Mild Hidradenitis Suppurativa
Description
The speaker outlined a practical, non-biologic approach to treating mild hidradenitis suppurativa (HS), defined by few nodules, infrequent flares, and limited quality-of-life impact. First-line topical care includes chlorhexidine or benzoyl peroxide washes, with sodium hypochlorite as a less irritating option, and clindamycin 1% as the main topical antibiotic. She also discussed emerging or off-label topicals such as resorcinol, ruxolitinib, clascoterone, and topical roflumilast, noting promising but limited evidence. Hormonal and metabolic therapies are often useful, especially spironolactone, drospirenone-containing combined oral contraceptives, finasteride in selected patients, metformin in those with insulin resistance or related conditions, and GLP-1 agents as an evolving area. Oral antibiotics, especially doxycycline, are used mainly as bridge or flare therapy, with clindamycin as another option. She reviewed supplements and adjuncts, including zinc with copper supplementation, vitamin D repletion when deficient, and turmeric. Additional procedural and supportive options include botulinum toxin for sweat-triggered disease and laser hair removal, particularly early in disease. Finally, she emphasized lifestyle measures such as loose breathable clothing, gentle skin care, a Mediterranean-style diet, limiting brewer’s yeast, low-impact exercise options like swimming or yoga, and weight and smoking management, ideally introduced after establishing rapport.
View moreConclusions
- Milder hidradenitis suppurativa can often be managed with a stepwise, non-biologic approach focused on symptom control and flare prevention.
- Topical cleansing agents, topical clindamycin, and emerging non-antibiotic topicals are core first-line options for mild HS.
- Resorcinol appears helpful for reducing flare duration, pain, and lesion size, but irritation limits its use and compounding is often required.
- Ruxolitinib, clascoterone, and roflumilast are promising newer topical therapies, though the evidence base is still limited and larger trials are needed.
- Hormonal and metabolic therapies such as spironolactone, combined oral contraceptives, finasteride, metformin, and possibly GLP-1 agents may benefit selected patients.
- Oral antibiotics are best used as bridge therapy or short courses for flares rather than as the sole long-term strategy.
- Supplements such as zinc, vitamin D, and turmeric may be reasonable adjuncts, but their supporting evidence is generally limited or anecdotal.
- Botulinum toxin may help patients whose HS is worsened by sweating or hyperhidrosis, with some improvement in quality of life shown.
- Laser hair reduction has evidence of benefit across devices and can reduce shaving- or waxing-triggered flares, especially in earlier disease.
- Lifestyle measures including breathable clothing, gentle skincare, diet modification, exercise adaptation, weight management, and smoking cessation should be part of comprehensive mild HS care.
- Scheinfeld N. Dermato Online J. 2014.
- Hargis A, et al. J Am Acad Dermatol. 2024;90(1):142-144.
- Grimstad, Kvammen, and Swartling. American Journal of Clinical Dermatology. 2020.
- Mahmoud et al.
- Shipman et al.